RJFSA
RNAC icon

Raymond James Financial Services Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Raymond James Financial Services Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-410
Closed -$51K – 3395
2021
Q2 		$51K Sell
410
-183
-31% -$21.8K ﹤0.01% 3208
2021
Q1 		$81K Buy
+593
New +$73.6K ﹤0.01% 3061

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial Services Advisors's RNAC Position: Q3 2021 in Review

Raymond James Financial Services Advisors sold out of Cartesian Therapeutics (RNAC) in Q3 2021, closing a stake of 410 shares — an estimated $51K sold.

Raymond James Financial Services Advisors first reported a position in RNAC in Q1 2021 and held it in 2 quarters. The position peaked at $81K in Q1 2021. 103 funds tracked by Wall St. Rank hold RNAC as of Q3 2021.

  • Raymond James Financial Services Advisors reported no remaining Cartesian Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 410 Cartesian Therapeutics shares in Q3 2021, an estimated $51K.
  • Raymond James Financial Services Advisors first reported a position in Cartesian Therapeutics in Q1 2021 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Cartesian Therapeutics position peaked at $81K in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.